Tissue kallikrein for the treatment of diseases associated with amyloid protein
US8501695B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Jul 18, 2008 |
| Grant date | Aug 6, 2013 |
| Priority date | — |
| Expiry date | Jul 11, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K38/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This invention relates to methods of treating Alzheimer's disease or symptoms thereof, and amnesic mild cognitive impairment or symptoms thereof. Methods of the invention include administering a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof. The invention further relates to uses of tissue kallikrein or a variant or active fragment thereof for the digesting or cleaving amyloid and the treatment of conditions benefiting from the digestion or cleavage of amyloid. The invention further relates to pharmaceutical compositions comprising a therapeutically effective amount of tissue kallikrein, variants or active fragments thereof formulated for oral or intranasal administration.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.